Canhelp Genomics

Canhelp Genomics A mRNA+AI company for Cancer Diagnosis

We are excited to share our strategic distribution partnership with Eurobio Scientific to help bring advanced precision ...
26/05/2026

We are excited to share our strategic distribution partnership with Eurobio Scientific to help bring advanced precision oncology diagnostics to more clinicians and patients across Europe and the UK.

The partnership will support access to Canhelp-Origin and Canhelp-UCa, two CE-IVD-certified molecular diagnostic assays designed to help inform cancer care through tissue-of-origin identification for cancers with uncertain primary sites and non-invasive urothelial carcinoma testing.

With Eurobio Scientific's strong European specialty diagnostics network and our precision oncology portfolio, this collaboration is an important step toward making innovative cancer diagnostics more accessible in everyday clinical practice.

Find more details about this exciting partnership on our official press release：https://www.canhelpgenomics.com/news_show?id=34

✨ Season’s Greetings from Canhelp Genomics ✨As the holiday season approaches, we would like to express our heartfelt tha...
24/12/2025

✨ Season’s Greetings from Canhelp Genomics ✨

As the holiday season approaches, we would like to express our heartfelt thanks to all our customers, clinicians, researchers, partners, and patients for your continued trust and support.

Your trust and confidence in Canhelp Genomics inspires our work every day -- advancing clinically meaningful, evidence-based precision oncology diagnostics, supporting informed treatment decisions, and ultimately improving patient care.

We truly value the partnerships we have built together and look forward to continuing this shared journey in the year ahead.

Wishing you, and your loved ones a holiday season filled with health, peace, and meaningful moments, and a happy and successful New Year！

🌍 Canhelp Genomics at ECP 2025 We were proud to showcase our flagship RNA + AI diagnostic solutions at Hall X5, Booth #...
10/09/2025

🌍 Canhelp Genomics at ECP 2025

We were proud to showcase our flagship RNA + AI diagnostic solutions at Hall X5, Booth #2, empowering accurate diagnosis and personalized treatment planning in oncology.

🔹 Canhelp-Origin – CE-IVD molecular tool integrating tumor RNA analysis with AI to identify the origin of poorly differentiated, undifferentiated, and metastatic tumors.

🔹 Canhelp-UCa – CE-IVD urine RNA test powered by proprietary AI, providing a noninvasive and reliable solution for detecting and monitoring urothelial carcinoma.

🔹 Canhelp CRC MSI – CE-IVD AI-powered assay for MSI testing in colorectal cancer, based on digitized H&E pathology slides.

Throughout the congress, we were delighted to engage with global distributors and experts. As we expand our footprint in Europe, we remain committed to fostering strong collaborations to drive innovation and shape the future of pathology.

👋 See you next time！

🎉Wonderful moments of 2025ECP!During the oral session, our team presented the latest research on Digital Pathology + AI ...
08/09/2025

🎉Wonderful moments of 2025ECP!

During the oral session, our team presented the latest research on Digital Pathology + AI approach.

Microsatellite instability (MSI) plays a critical role in colorectal cancer (CRC) diagnosis and treatment. The Promega MSI assay is widely used but has limitations in terms of cost, time, and tissue requirements. This study aimed to compare the consistency of Deepath-MSI, a whole slide image (WSI)-based approach, with the traditional Promega MSI assay in assessing MSI status in CRC.

🔹High accuracy: 96% sensitivity, 92% specificity in surgical CRC specimens.
🔹Efficiency boost: Reduced traditional PCR testing by 87% in surgical specimens and 82% in biopsy samples.

📍 Visit us at Hall X5, Booth #2 to explore the innovations shaping the future of pathology!

✨ Exciting moments at the 37th European Congress of Pathology!During the 7 September 2025 oral session, Canhelp Genomics...
08/09/2025

✨ Exciting moments at the 37th European Congress of Pathology!

During the 7 September 2025 oral session, Canhelp Genomics unveiled our newest innovation in tumor origin identification.

Squamous cell carcinoma (SCC) and urothelial carcinoma often share similar histology and immunophenotypes, making it hard for conventional pathology to accurately identify their tissue of origin.That’s why we developed Deepath-SCC, a deep learning model designed to improve the accuracy and interpretability of SCC tissue origin identification.

🔹Primary SCCs: 96.9% overall accuracy (94.7–98.5% across subtypes)
🔹Metastatic SCCs: 91.9% overall accuracy (78.6–100% across subtypes)

Deepath-SCC offers a fast, cost-effective, and reliable solution—especially valuable for cases with unknown or multiple primary SCCs.

📍Visit us at Hall X5, Booth #2 to see how Canhelp Genomics can elevate your diagnostics and research!

🚀 Canhelp Genomics at ECP 2025We are excited to join the 37th European Congress of Pathology (ECP) to showcase our lates...
02/09/2025

🚀 Canhelp Genomics at ECP 2025
We are excited to join the 37th European Congress of Pathology (ECP) to showcase our latest RNA-based and AI-powered diagnostic innovations.

📢 Scientific Programme Highlight
Don’t miss our oral presentation on Sunday, 7 September, 11:36–12:00, where we will share data from two new studies:
• Deepath-SCC: a deep learning model for accurate tissue origin identification in squamous cell carcinoma
• Prospective Evaluation of Deepath-MSI for Microsatellite Instability Assessment in Colorectal Cancer: A Novel Whole Slide Image-Based Approach Versus Promega MSI Assay

🤝 Visit us at Hall X5 Booth 2 to meet our team and explore how we can support your clinical work.

We look forward to seeing you in Vienna!

We're thrilled to share a major milestone from Canhelp Genomics: Our deep learning model Deepath-MSI—designed for micros...
01/09/2025

We're thrilled to share a major milestone from Canhelp Genomics:

Our deep learning model Deepath-MSI—designed for microsatellite instability (MSI) detection in colorectal cancer (CRC) using whole-slide imaging—has been published in a leading oncology journal, marking a leap forward in clinical pathology AI.

Standout Clinical Performance
In a real-world validation study of 2,236 CRC samples, Deepath-MSI delivered exceptional results: At a 95% sensitivity threshold (critical for avoiding false negatives in clinical care), it achieved ~91% specificity and accurately excluded approximately 90.7% of microsatellite-stable (MSS) patients from further follow-up molecular testing (e.g., IHC/PCR). This directly lightens the burden of resource-intensive ancillary tests, streamlines diagnostic workflows, and speeds up treatment decision-making for CRC patients globally.

A Pioneering Recognition
Deepath-MSI is the first AI-powered computational pathology model to receive the "Innovative Medical Device" designation from China's National Medical Products Administration (NMPA)—a testament to its clinical relevance, technical innovation, and potential to transform standard care. It has also obtained EU CE certification for colorectal cancer MSI detection that underscores its clinical reliability and global applicability.

Open for Global Collaboration
We're committed to advancing CRC diagnostics worldwide: Researchers and clinicians across the globe are invited to apply for free access to Deepath-MSI. Simply send an email to [email protected] to request your trial and join us in improving MSI screening accessibility.

Let's work together to make precise, efficient CRC biomarker detection a reality for every care setting.

Breaking news! We’re proud to announce that Gene Expression Test System for Human Urothelial Cancer Detection (Canhelp-U...
23/07/2025

Breaking news! We’re proud to announce that Gene Expression Test System for Human Urothelial Cancer Detection (Canhelp-UCa) was officially approved by NMPA (China’s FDA).

The Canhelp-UCa test is a CE-IVD multi-target urine RNA test combined with proprietary AI algorithms, offering a promising approach for the noninvasive detection and surveillance of urothelial carcinoma, including bladder cancer, as well as renal pelvis and ureter carcinomas.

Multicenter prospective clinical study demonstrated that the product achieved a clinical sensitivity of 95.9%, specificity of 94.5%, and an overall concordance rate of 95%, delivering high detection rates across all tumor stages and subtypes.

Open to partnerships — contact us to explore collaboration!

🎊Milestone！We’re thrilled to announce that Canhelp® CRC-MSI has achieved acceptance into China’s Special Review Procedu...
16/04/2025

🎊Milestone！We’re thrilled to announce that Canhelp® CRC-MSI has achieved acceptance into China’s Special Review Procedure for Innovative Medical Devices.

🚀Canhelp® CRC-MSI is AI-powered diagnostic tool, designed for colorectal cancer microsatellite instability (MSI) testing using digitized hematoxylin and eosin (H&E)-stained pathology slides.

👨‍⚕️MSI Testing: A game-changer for Lynch syndrome screening, colorectal cancer prognosis, and treatment decisions. We’re excited to speed up its clinical use, delivering hope to more colorectal cancer patients!

🎉Happy Chinese New Year！🎉
28/01/2025

🎉Happy Chinese New Year！🎉

Address

Lvzhou Road 99
Hangzhou
311100

Telephone

400-168-3904

Website

Alerts

Be the first to know and let us send you an email when Canhelp Genomics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Canhelp Genomics:

Shortcuts

Share

Category